Search results

Australia’s best known carnivorous dinosaur Australovenator is under the microscope at ANSTO

This afternoon, the Chair of ANSTO, Dr Annabelle Bennett, wrote to all staff to let them know that CEO Dr Adi Paterson has decided to resign. She said the Board is deeply appreciative of the contributions Adi has made, including to the health, research and academic outputs of ANSTO during his tenure. Mr Shaun Jenkinson will continue as Acting CEO, while the Board undertakes a global search for a permanent CEO.

Minister for Industry and Science, the Hon Ed Husic MP has formally announced the appointment of Mr Andrew Carriline as ANSTO Board Deputy Chairperson, effective from Thursday 9 May 2024.

nandin is ANSTO’s Innovation Centre where science and technology entrepreneurs, startups and graduates meet industry expertise to experiment, co-create, innovate, and commercialise, creating new jobs in the high-growth industries of tomorrow.

The work of the group comprises Radioactivity Measurement Standards, Radioanalytical chemistry, Environmental Radioactivity Measurement Centre, Nuclear security science and Environmental monitoring.

ANSTO offers accelerator-based particle-induced gamma-ray emission techniques to determine total fluorine concentration in a range of solid materials and rapidly screen for the presence of PFAS (perfluoroalkyl and polyfluoroalkyl substances).

Accelerator technique used in pioneering biomaterials research led by the University of Sydney.

ANSTO recently hosted a public Ask Us Anything event on nuclear medicine, sharing information on how we safely manufacture and distribute nuclear medicine across Australia each week to hundreds of hospitals and clinics.

General manager ANSTO Communications and Stakeholder Engagement was one of the presenters at the IAEA W4NSEC workshop

Researchers have discovered a 380-million-year-old heart – the oldest ever found – alongside a separate fossilised stomach, intestine and liver in an ancient jawed fish, shedding new light on the evolution of our own bodies.

The Government is safeguarding Australia’s sovereign capability to produce vital nuclear medicines by launching a $30 million project to design a new world-leading manufacturing facility to be built at Lucas Heights in Sydney.

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO has secured a $1.62 million Medical Research Future Fund (MRFF) grant under the Australian Brain Cancer Mission’s 2024 Brain Cancer Discovery and Translation program, administered by the Department of Health and Aged Care.  

ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.

Unique opportunity to contribute to the long term conservation of Australia’s most iconic landmark: The Sydney Harbour Bridge.